Esperion Therapeutics
ESPR
ESPR was delisted on the 10th of July, 2026.
113 hedge funds and large institutions have $366M invested in Esperion Therapeutics in 2015 Q4 according to their latest regulatory filings, with 21 funds opening new positions, 37 increasing their positions, 31 reducing their positions, and 28 closing their positions.
50% more funds holding in top 10
Funds holding in top 10: 2 → 3 (+1)
19% more repeat investments, than reductions
Existing positions increased: 37 | Existing positions reduced: 31
7% less funds holding
Funds holding: 121 → 113 (-8)
7% less capital invested
Capital invested by funds: $392M → $366M (-$26.1M)
15% less call options, than puts
Call options by funds: $3.62M | Put options by funds: $4.24M
25% less first-time investments, than exits
New positions opened: 21 | Existing positions closed: 28
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Renaissance Technologies
New York
|
+$9.11M |
| 2 |
State Street
Boston,
Massachusetts
|
+$8.82M |
| 3 |
CCI
Columbus Circle Investors
|
+$7.96M |
| 4 |
BFA
BlackRock Fund Advisors
San Francisco,
California
|
+$6.95M |
| 5 |
SAM
Senzar Asset Management
New York
|
+$5.64M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
-$16.6M |
| 2 |
PC
Polar Capital
London,
United Kingdom
|
-$7.3M |
| 3 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$5.64M |
| 4 |
HCM
Highbridge Capital Management
New York
|
-$5.58M |
| 5 |
Voloridge Investment Management
Jupiter,
Florida
|
-$5.05M |
ESPR Hedge Fund Activity: Q4 2015 in Review
113 of the 3,824 institutional investors tracked by Wall St. Rank reported a position in Esperion Therapeutics (ESPR) for Q4 2015, worth a combined $366M — down 6.7% from $392M a quarter earlier.
Sellers outnumbered buyers: 28 funds closed out of ESPR and 21 opened new positions — a net loss of 7 holders — while 31 trimmed existing stakes and 37 added.
The largest buyer was Renaissance Technologies, opening a new position worth an estimated $9.11M. The largest seller was Fidelity Investments, cutting an estimated $16.6M.
- 113 institutional investors held Esperion Therapeutics (ESPR) as of Q4 2015, down from 121 in Q3 2015.
- Funds reported $366M of Esperion Therapeutics stock for Q4 2015, down 6.7% quarter-over-quarter.
- 21 funds opened new Esperion Therapeutics positions in Q4 2015 and 28 closed out, a net change of -7 holders.
- The largest Esperion Therapeutics buyer in Q4 2015 was Renaissance Technologies, an estimated $9.11M added.
- The largest Esperion Therapeutics seller in Q4 2015 was Fidelity Investments, an estimated $16.6M sold.
Based on aggregated 13F filings for Q4 2015.